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Human papillomavirus (HPV) is the etiologic risk factor for cervical cancer. Some studies have suggested an association with a subset
of lung tumors, but the etiologic link has not been firmly established. We performed an international pooled analysis of crosssectional studies (27 datasets, n = 3249 patients) to evaluate HPV
DNA prevalence in lung cancer and to investigate viral presence
according to clinical and demographic characteristics. HPV16/18
were the most commonly detected, but with substantial variation
in viral prevalence between geographic regions. The highest prevalence of HPV16/18 was observed in South and Central America,
followed by Asia, North America and Europe (adjusted prevalence
rates = 22, 5, 4 and 3%, respectively). Higher HPV16 prevalence
was noted in each geographic region compared with HPV18, except
in North America. HPV16/18-positive lung cancer was less likely
observed among White race (adjusted odds ratio [OR] = 0.33, 95%
confidence interval [CI] = 0.12–0.90), whereas no associations were
observed with gender, smoking history, age, histology or stage.
Comparisons between tumor and normal lung tissue show that
HPV was more likely to be present in lung cancer rather than normal lung tissues (OR = 3.86, 95% CI = 2.87–5.19). Among a subset
of patients with HPV16-positive tumors, integration was primarily among female patients (93%, 13/14), while the physical status
in male cases (N = 14) was inconsistent. Our findings confirm that
HPV DNA is present in a small fraction of lung tumors, with large
geographic variations. Further comprehensive analysis is needed to
assess whether this association reflects a causal relationship.

Introduction
Lung cancer is the third most common cancer in men and women of
all races and the leading cause of cancer death in the United States and
worldwide. Cigarette smoking is the primary risk factor and accounts
for ~85% of all lung cancer cases. Other less prevalent risk factors are
genetic factors, family history of lung cancer and exposures to radon,
asbestos, arsenic, diesel exhaust and some forms of silica and chromium. Human papillomavirus (HPV) is a small non-enveloped DNA
tumor virus of the family Papillomaviridae and is the established
etiological agent of genital warts, cervical cancer and a proportion of
cancers of the vulva, vagina, penis, anus and oropharynx (1,2). More
than 100 different genotypes have been identified, and types 16 and
18 are the most common oncogenic types, leading to the development
of ~70% of all cervical carcinomas.
In 1979, Syrjänen first hypothesized that certain types of HPV
are responsible for causing cancer in the lung (3). In the last three
decades, the number of reports suggesting an association between
HPV and lung cancer has increased tremendously. A review of HPV
in 2468 lung cancer cases was first published in 2002 and showed
that, using morphological, immunohistochemical and HPV DNA
detection methods (4), ~22% of the cases analyzed contained HPV.
This meta-analysis was updated in 2007 and reported a prevalence of
24.5%, but considerable heterogeneity was observed between studies (5). In our meta-analysis in 2009 (6), we also identified a wide
variation in the prevalence of HPV in lung cancer tissues, despite the
fact that only studies utilizing PCR-based methods for HPV detection
were included in order to reduce the heterogeneity between studies.
Nevertheless, HPV16 and 18 were the two most common genotypes
detected in lung tumors, and a higher prevalence of HPV16 and 18
was noted in Asian populations compared with European populations.
In 2012, the most recent meta-analysis was published and reported
that the variability of HPV prevalence may be due to differences in
geographical study origin and histological types of lung cancer rather
than the method of HPV detection (7). However, meta-analyses findings to date have limitations because important characteristics such as
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gender, tumor stage and smoking status of HPV-positive lung cancer
patients have not been taken into account. To address these limitations,
we have conducted an international, multi-institutional, pooled analysis of studies to further analyze the characteristics of cases observed
with HPV16/18 DNA with particular emphasis on race, gender, smoking status, tumor stage as well as histology of the cancers. The most
recent meta-analysis has been updated (7); prevalence rates of HPV in
lung tumors by geographic region, adjusted for age, gender, smoking
status and tumor stage are presented. Because the majority of studies
to date have been conducted in Asian and European populations, comparisons of demographic and clinical characteristics of HPV-positive
lung cancer cases were also made between North American cases and
the rest of the world.

SCC data were extracted from one publication (8) and the adenocarcinoma
data from the other (9). The majority of studies to date were conducted in
Asian and European populations. Data from two published abstracts (31,32)
and two unpublished datasets (E.Taioli et al. and A.Zaravinos et al., unpublished results) have also been included in this pooled analysis. These cases
were recruited from three medical institutions in the United States and one
from Greece. This resulted in 79 published studies and 2 unpublished studies,
which include 7440 lung cancer cases. Sixteen studies also reported the prevalence of HPV in non-tumor lung tissues (i.e. in adjacent normal tissues from
lung cancer cases or in lung tissues from non-cancer cases) (13,17,20,25,33–
44). These data are included as a subset analysis comparing HPV prevalence
between tumor and normal lung tissue. In order to describe the characteristics
of all eligible studies, the following information were extracted for each study:
first author, year of publication, geographic region, study size, method of HPV
detection, HPV types detected and HPV status overall and when available,
according to gender, smoking status, tumor stage and histology.

Materials and methods

Pooled analysis data collection
Following Institutional Review Board approval, invitations to participate in the
pooled analysis were prepared for the principal investigators of the 81 eligible
studies. Invitations were not successfully sent to investigators of 13 studies
due to inactive or unavailable contact information. Although no response or
a refusal to participate was received from 47 studies, only 41 were excluded
because 6 of these studies reported individual-level data in the publications.
Datasets with age, gender, tumor stage, smoking status, histological type and
HPV results were created for each of these studies and were included in the
pooled analysis (8,9,26,38,45–47). In total, 27 studies were included in the
pooled analysis (8,9,11,13,14,26,31,32,34,38,45–60) including the studies of
E.Taioli et al. and A.Zaravinos et al. (unpublished results).
Verification of cancer diagnosis was reported in the corresponding
publications for 21 of the 27 studies (8,9,11,13,14,26,34,38,45–50,53–
60). If not explicitly stated in the published article, authors were contacted to clarify what, if any, efforts were made to avoid contamination.
Efforts to avoid contamination were reported for 22 of the 27 studies

Literature review and data extraction
A flow diagram that summarizes the literature review process and selection of
datasets for inclusion in the pooled analysis is described in Figure 1. A bibliographic search was carried out in the PubMed database to identify the studies
that evaluated HPV status of primary lung tumors published up to July 2013.
The search strategy used was: (HPV OR HPV) AND (lung OR bronchogenic)
AND (cancer OR carcinoma). A manual review of the bibliographic references
cited in the selected papers was also undertaken to retrieve papers that might
have been missed in the initial search. From this search, 90 publications were
identified. When the data were reported from the same cohort (8–30), only the
most recent publication or one that had the larger cohort of lung cancer cases
was included (10,13,14,17,20,21,25,26,30). Two publications had overlapping
squamous cell carcinoma (SCC) cases (8,9) but only one reported data for
adenocarcinoma cases (9). Therefore, although counted as a single study, both
publications were included. To ensure that the larger cohort was included, the

Fig. 1. Flow diagram summarizing the identification and selection process of eligible studies for inclusion in the pooled analysis.
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(8,9,11,13,26,31,32,34,38,45–48,50–52,54–56,58,59) and for E.Taioli et al.
and A.Zaravinos et al. (unpublished results), and all studies reported the inclusion of internal quality controls and/or positive and negative HPV controls.
From the pooled dataset, 65 cases were excluded: 51 because of inadequate
DNA based on quality control checks performed by the submitting investigator
(54), 2 because they were duplicate samples (A.Zaravinos et al., unpublished
results) and 12 because they were metastasis to the lung (13,57,59,60). The
pooled analytic dataset included 3249 cases.
Published abstracts and unpublished studies
For E.Taioli et al. (unpublished results; n = 69), all cases were histologically
confirmed lung cancer patients diagnosed at New York University (NYU)Bellevue Hospital from 1993 to 1999. The central pathology registry at NYUBellevue Hospital was used to identify all consecutive African American cases;
clinical charts were then retrieved using the pathology report number, and personal/behavioral information was collected. The pathologist reviewed all the
tissue blocks to make sure that a block containing material from the primary
lung tumor was used for testing. DNA from formalin-fixed paraffin-embedded
(FFPE) tissues was extracted and tested for HPV, and physical status was determined for all HPV16-positive samples. For A.Zaravinos et al. (unpublished
results; n = 17), all cases were histologically confirmed lung cancer patients
diagnosed at the Department of Surgical Pathology of the University of Crete
from 2007 to 2011. About 5–10 serial tissue sections of 10 µm were cut from
each FFPE block and stained with hematoxylin and eosin (H&E) before microscopic examination. When the proportion of tumor cells was >70%, the FFPE
block was subjected to DNA extraction. Data from Mehra et al. (32) (n = 62)
were published in the 2013 Proceedings of the American Association for
Cancer Research. All cases were a convenience sample of randomly selected
histologically confirmed lung cancer patients (enriched for non-smoking
status and adenocarcinoma) diagnosed at Fox Chase Cancer Center (FCCC)
from 1993 to 2010. FFPE tissues and corresponding demographic and clinical information were obtained from the FCCC Biosample Repository. DNA
from tumor tissue was extracted and tested for HPV, and physical status was
determined for all HPV16-positive tumor tissues. Data from Pillai et al. (31)
(n = 208), were published in the 2013 Proceedings of the American Society of
Clinical Oncology. All cases were histologically confirmed surgically resected
lung cancer patients diagnosed at Wellstar Health Systems, Atlanta, GA, from
2002 to 2008. The samples were consecutively acquired paraffin-embedded
tissues, archived in a temperature controlled storage area until ready for analysis. Details of the tissue acquisition have been described previously (61). DNA
from FFPE tissues was extracted and tested for HPV, and physical status was
evaluated for all HPV16-positive tissues.
HPV detection and genotyping
The HPV testing for the published abstracts and unpublished dataset (E.Taioli
et al., unpublished results) was performed in a single laboratory. DNA was
extracted from FFPE lung cancer tissues using ArchivePure DNA purification
kit (5 Prime). DNA concentration and quality checks were performed by evaluating 260:280 ratios as well as PCR amplification of a β-globin amplicon using
the RS 42 and KM 29 primers. For the E.Taioli et al. (unpublished results)
samples, HPV status was determined by nested HPV PCR reactions using
PGMY09/11, followed by GP5+/GP6+ primers. Briefly, 20 µl PCR amplifications were performed using a GeneAmp PCR System® 9700 (Applied
Biosystems, Life Technologies) at 95°C for 9 min, 40 cycles of 95°C for 30 s,
55°C for 1 min and 72°C for 10 min with a final extension of 72°C for 5 min.
The nested PCR reaction was performed by prediluting 1:100 PCR products
from the initial reaction in a final reaction volume of 25 µl. The cycling conditions were 95°C for 10 min, 40 cycles of 95°C for 1 min, 55°C for 1 min and
72°C for 1 min, followed by a final extension at 72°C for 5 min. Negative and
positive controls were included in each PCR reaction. The PCR products were
separated in 2% agarose gel by electrophoresis and HPV genotyping of positive
samples were performed using the Linear Array HPV Genotyping kit (Roche
Diagnostics) according to the manufacturer’s instructions. For the Mehra et al.
and Pillai et al. samples, HPV testing was performed using the INNO-LiPA
genotyping Extra Amplification and Genotyping Extra kits (Innogenetics,
Belgium). The SPF10 PCR primers are capable of identifying a broad spectrum of HPV genotypes by amplifying a 65 bp target in the HPV L1 sequence.
Genotyping of positive HPV samples was performed using the LiPA genotyping protocol that involves a reverse hybridization line probe assay to detect 18
high-risk types (16,18,26,31,33,35,39,45,51–53,56,58,59,66,68,73,82), 7 lowrisk types (6,11,40,43,44,54,70) and additional types (69,71,74). Negative and
positive controls (HPV6), as well as an internal control (HLA-DPB1 gene),
to confirm DNA quality and the absence PCR inhibitors, were included in
the assay.
HPV testing for the second unpublished study was performed by the submitting investigator (A.Zaravinos et al., unpublished results). Lung cancer
tissue sections (FFPE) were deparaffinized with xylene and ethanol washes,

treated with protease and then DNA from tumor tissue was extracted using the
QIAmp DNA minikit (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Briefly, tissue sections were digested with 0.1 mg/ml proteinase
K (Promega, Madison, WI) and 400 µl of digestion buffer containing 150 mM
NaCl, 400 mM Tris–HCl, 60 mM ethylenediaminetetraacetic acid and 15%
sodium dodecyl sulfate, pH 8.0, in a 1.5 ml eppendorf tube. Samples were
then incubated at 60°C for 2 days. Fresh proteinase K was added three times
daily. The samples were extracted once with phenol/chloroform and once with
chloroform. DNA was precipitated by the addition of 20 µl of 5 M NaCl and
1 ml of ethanol, recovered by centrifugation for 15 min, washed once with
cold 70% ethanol and resuspended in 50 µl of double distilled water. DNA
concentration was calculated using the NanoDrop™ 1000 Spectrophotometer.
Specimens were examined for the presence of amplifiable DNA using a set
of primers for the β2-microglobulin gene. Amplification of HPV DNA in the
specimens was performed by PCR using specific primer pairs for each E6 gene
region of the HPV6, -11, -16, -18 and -33 subtypes. The samples were initially
examined for the presence of non-type-specific HPV DNA using the general
HPV primers, GP5+/GP6+. The following PCR amplification cycling conditions were used: 94°C for 4 min; 40 cycles, 94°C for 1 min, 40°C for 2 min
and 72°C for 1–5 min. The last cycle was extended by a 4 min elongation at
72°C. Appropriate negative and positive controls were included in each PCR
reaction in order to exclude contamination events and to establish the specificity of primer-directed amplification. Recombinant plasmids carrying HPV
type-specific sequences served as positive controls for HPV6, -11, -16, -18 and
-33 genomes detection. For the general screening of HPV DNA, HeLa cells
transfected with conserved L1 sequences among HPV strains were used as
the positive control. PCR was carried out in a total volume of 25 µl containing 5 mM of 5× Green GoTaq reaction buffer, 1.5 mM MgCl2, 0.2 mM of each
deoxynucleotide triphosphate (dNTPs), 0.6 U of GoTaq Flexi DNA polymerase (Promega) and 200 ng of genomic DNA. The PCR products were examined
by electrophoresis on a 2% agarose gel and photographed on an ultraviolet
light transilluminator. The sensitivity of the PCR assay was determined by
applying a serial-dilution amplification assay of viral-positive control DNA.
HPV physical status
The physical status of HPV16 was assessed in HPV16-positive lung cancer
tissues for three published studies that were included in the pooled analysis (32,48,49) using the same quantitative PCR assay as described previously (62). Each HPV16 DNA-positive sample was amplified for 76 bp of
the E2 gene using the following primers: forward 5′-AACGAAGTATCC
TCTCCTGAAATTATTAG-3′ (3361–3389 nt); reverse 5′-CCAAGGCG
ACGGCTTTG-3′ (3427–3443 nt), as well as 81 bp of the E6 gene, primers forward 5′-GAGAACTGCAA TGTTTCAGGACC-3′ (94–116 nt);
reverse 5′-TGTATAAGTTGTTTGCAGC TCTGTGC-3′ (150–169 nt),
in the presence of specific hybridization probes for E2-(FAM-CACCC
CGCCGCGACCCATA-TAMRA) (3406–3424 nt) and E6-(FAM-C
AGGAGCGAC CCAGAAAGTTACCACAGTT-TAMRA) (119–147 nt). The
cycling conditions were 2 min at 50°C, 10 min at 95°C, and a two-step cycle of
95°C for 15 s and 60°C for 60 s for a total of 40 cycles. A standard curve was
generated from 8-fold serial dilution of p1203 PML2d HPV16 (Addgene plasmid 10869, deposited by Peter Howley, MD; Addgene, Cambridge, MA). Both
HPV16-positive cell lines, SiHa and Caski DNA were included as controls.
The assay was performed in duplicate for each sample. Physical status was
determined by calculating the ratios of E2 to E6 where a ratio <1.0 indicates
a predominance of integrated HPV genomes, >1.0 indicates a predominance
of episomal genomes. The results were recorded as copy numbers per 20 ng
of DNA.
Statistical analysis
All statistical analyses were carried out using SAS 9.3 (SAS Institute, Cary,
NC) with a significant level of 0.05 and evaluation of publication bias was performed using the Comprehensive Meta Analysis Version 2 software (Biostat,
Englewood, NJ). The adjusted HPV prevalence of each region was calculated
after adjusting for age, gender, smoking history, tumor stage and study and
reported as an estimated probability of HPV-positive lung cancer patients with
95% confidence intervals (CIs). Random effects logistic regression models
were used to determine the association between HPV16/18 status and clinical
and demographic variables. Study was used as a random effect to allow deviation caused by different study conditions. In the international pooled dataset,
one out of three of the subjects was missing either smoking history or tumor
stage. Both variables, we believe, are important in understanding the nature of
HPV16/18 prevalence. However, exclusion of subjects with missing values is
inefficient and can lead to biased results if those dropped are atypical in some
respect. Therefore, multiple imputations were performed prior to regression
analyses using IVEware. Ten imputation datasets were generated and final
model estimates were combined using SAS 9.3. For each imputed dataset, the
missing values were drawn from other observed data (63). The uncertainty
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about the correct model for non-response was captured by the variance across
multiple imputed datasets. Subjects with one or part of the covariates missing were included in the analysis and hence, no information was lost due to
exclusion.

Results
Twenty-seven of the 81 eligible studies elected to participate in this
pooled analysis and the resulting pooled dataset included 3249 cases,
whereas the remaining 54 studies had 4199 cases. Detailed characteristics

of each study in the pooled dataset are summarized in Table I.
The majority of cases in the pooled dataset were from Asia (40%,
1312 cases) and Europe (34%, 1100 cases). North/South American
studies represented 26% of all cases in the pooled dataset (n = 837).
For the non-included studies, the majority of cases were also from
Asia (55%, 2332 cases) and Europe (33%, 1404 cases), whereas 7%
of cases (n = 299) were from North/South America and 4% (n = 164
cases) from other geographic regions (Australia and the Middle East).
The size of studies in the pooled dataset varied from 17 to 399 cases,
whereas the non-included study sizes ranged from 5 to 319 cases.

Table I. Characteristics of studies included in the pooled analysis and adjusted HPV prevalence
Study

Tissue source

Asia (N = 1312)
Baba et al. (N = 77) (49)
Kinoshita et al. (N = 34) (57)
Iwakawa et al. (N = 275) (53)
Hiroshima et al. (N = 49) (52)
Goto et al. (N = 296) (51)
Lim et al, 2009 (N = 99) (56)

FFPE
FF
FF
FFPE
FFPE
FFPE

Method of HPV detection

Histological type

HPV types detected

AC, SCC
AC, SCC, ASqa, LCCa, SmCCa
AC
AC, SCC
AC, SCC, CSrca
AC

HPV 6, 16, 18, 33
HPV 18
HPV negative
HPV 16
HPV 6, 11, 16, 18
HPV negative

AC, SCC
SCC
AC

HPV 6, 11, 16, 18
HPV 6, 16, 18
HPV16, HPV18

ASq

HPV 6, 11, 16, 18

SCC
AC, SCC, other
AC, SCC, ASqa, LCCa,
SmCCa, NSCLCa, othera
AC, SCC, LCCa
ACe, SCCe, LCCa, NSCLCa

HPV 16, Xd
HPV 6, 16
HPV 6, 16, 18, 31, 53,

PCR (TS: HPV 16, 18; SPF10
primers (n = 92)
Carpagnano et al. (N = 89) (34)
FFPE and BBb
PCR (consensus HPV primers)
Nuorva et al. (N = 22) (46)
FFPE
PCR (MY09/MY11)
van Boerdonk et al. (N = 220) (59) FFPE
PCR (GP5+/GP6+)
Adjusted HPV 16/18 prevalence (95% CI)f = 3.03% (2.76, 3.30)
Adjusted HPV 16 prevalence (95% CI)f = 2.94% (2.68, 3.21)
Adjusted HPV 18 prevalence (95% CI)f = 0.82%(0.73, 0.92)
South and Central America (N = 105)
Castillo et al. (N = 36) (50)
FFPE
PCR (GP5 + 6+) and SB
Aguayo et al. (N = 69) (48)
FFPE
PCR (GP5+/GP6+) and SB
Adjusted HPV 16/18 prevalence (95% CI)f= 21.90% (19.61, 24.20)
Adjusted HPV 16 prevalence (95% CI)f = 19.18% (16.88, 21.49)
Adjusted HPV 18 prevalence (95% CI)f = 7.78% (6.61, 8.95)
North America (N = 732)
 Taioli et al. (unpublished results,
FFPE
PCR (PGMY09/PGMY11/
N = 69)
GP5+/6+)
Pillai et al. (N = 208) (31)
FFPE
PCR (SPF10, Inno-LIPA)
Mehra et al. (N = 62) (32)
FFPE
PCR (SPF10, Inno-LIPA)

AC, SCC, LCC, SmCC, other

HPV 16, 18

AC, SCC, SmCC
AC
AC, SCC, LCC, NSCLCe

HPV 16, 30, 31, 39,
HPV 6, 11, 16, 18, 31, 33
HPV negative

AC, SCC, SmCCe
AC, SCC

HPV 16, 18, 33
HPV 6, 16, 18, 31, 45

AC, SCC, LCCa, NSCLCa,
othere
AC, SCC, ASqe, LCC, othere
AC, SCCe, ASqa, LCCa,

HPV 51, X

Joh et al. (N = 29) (38)
FF
PCR (GP5+/GP6+)
Yanagawa et al. (N = 330) (60)
FFPE
PCR (GP5+/GP6+) and ISH
Bohlmeyer et al. (N = 34) (45)
FFPE
PCR (MY09/MY11)
Adjusted HPV 16/18 prevalence (95% CI)f = 3.78% (3.35, 4.22)
Adjusted HPV 16 prevalence (95% CI)f = 2.03% (1.68, 2.39)
Adjusted HPV 18 prevalence (95% CI)f = 2.49% (2.23, 2.75)

AC, SCCe, LCCa, NSCLCa
AC, SCC
SCC

PCR (SPF10, Inno-LIPA)
PCR (TS: HPV 16, 18, 33)
PCR (TS: HPV 16, 18, 33)
PCR (TS: HPV 16, 18, 33)
PCR GP5+/GP6+
ISH (HPV6, 11, 16, 18, 31,
33, 35, 45, 51, 52, 56, 58, 66)
Miyagi et al. (N = 176) (8,9)
FFPE
PCR (TS: HPV 6, 11, 16, 18)
Hirayasu et al. (N = 73) (26)
FFPE
PCR (TS: HPV 6, 11, 16, 18)
Wang et al. (N = 210) (58)
FFPE, Bxb, PEb
PCR (MY09/MY11 and TS: HPV
16, 18)
Tsuhako et al. (N = 23) (47)
FFPE
PCR (TS: HPV 6, 11, 16, 18)
Adjusted HPV 16/18 prevalence (95% CI)c = 4.60% (3.48, 5.73)
Adjusted HPV 16 prevalence (95% CI)c = 1.49% (0.86, 2.11)
Adjusted HPV 18 prevalence (95% CI)c = 1.09% (0.66, 1.52)
Europe (N = 1100)
Syrjanen et al. (N = 131) (14)
FFPE
ISH (HPV6, 11, 16, 18, 30)
Syrjanen et al. (N = 77) (55)
FFPE
PCR (MY09/MY11/GP5+/GP6+)
Giuliani et al. (N = 77) (13)
FFPE and FF
PCR (MY09/MY11/GP5+)

Gorgoulis et al. (N = 68) (11)
 Zaravinos et al. (unpublished
results, N = 17)
Koshiol et al. (N = 399) (54)

FFPE and FF
FFPE

PCR (MY09/MY11/GP5+/GP6+)
PCR (GP5+/GP6+)

FFPE

HPV negative
HPV negative

HPV 6, 16, 18, 39, 53, X
HPV 6, 16, 18, 52, 53, 44,
68, 39, 74, 82, X
HPV 11, 16
HPV negative
HPV 18

Other: histological type, not otherwise specified. AC, adenocarcinoma; ASq, adenosquamous carcinoma; BB, bronchial brushing; Bx, biopsy tissue; CSrc,
carcinosarcoma; FF, fresh frozen; ISH, in situ hybridization; LCC, large cell carcinoma; NSCLC, non-small-cell lung carcinoma, not otherwise specified; PE,
pleural effusion; SB, Southern blot; SmCC, small cell carcinoma; TS, type-specific primers.
a
Number of cases ≤6.
b
Cancer cells present and confirmed by pathologist.
c
Study is included in the model as a random effect.
d
Type not defined; HPV+ (for the HPV6/11/16/18/30 panel).
e
Number of cases 7–10.
f
Study is included as a covariate in the model.
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All studies included in the pooled analysis performed HPV DNA
testing on surgical tissue (FFPE and/or frozen) or biopsy specimens.
Similarly the non-included studies performed HPV DNA testing
on surgical or biopsy tissue specimens except for one study which
utilized bronchial aspirates from lung cancer patients (64). Most of
the studies in the pooled analysis as well as the non-included studies used PCR-based methods for HPV DNA detection, 93 and 80%,
respectively. Although adenocarcinoma and SCC were the most common histological types included in the pooled dataset (56%, 1808
cases and 38%, 1220 cases, respectively) and in the non-included
studies (33%, 1404 cases and 57%, 2379 cases, respectively), the
pooled analysis consisted of a larger proportion of adenocarcinoma
cases compared with the non-included studies. Similar proportions of
other histological types were represented in both the pooled dataset
and non-included studies (7%, 214 cases and 8%, 350 cases, respectively). Histology was not specified for 7 (0.2%) cases in the pooled
dataset and for 68 (1.6%) cases in the non-included studies.
The predominant high-risk HPV types found in lung cancer
patients were HPV 16 and HPV18 (Table I). Other high-risk HPV
types (HPV31, 33, 35, 45, 51, 52, 68 and 82) were also detected. For
all geographic regions (Asia, Europe as well as North America) and
with the exception of South and Central America, large-to-moderate
heterogeneity was observed between the studies with no evidence of
publication bias (data not shown). In order to address the heterogeneity, HPV prevalence rates were calculated after adjusting for age,
gender, smoking history and tumor stage; study was included as a
random effect where appropriate (Table I). Significant differences in
HPV16/18 prevalence were noted between geographic regions. HPV
16/18 was most prevalent in South and Central America (adjusted
prevalence [AdjPr] = 21.90%, 95% CI = 19.61–24.20), followed
by Asia (AdjPr = 4.60%, 95% CI = 3.48–5.73), North America
(AdjPr = 3.78%, 95% CI = 3.35–4.22) and Europe (AdjPr = 3.03%,
95% CI = 2.76–3.30). For each geographic region, the prevalence of
HPV16 was significantly higher than HPV18, with the exception of
North America and Asia. South and Central America had the highest
prevalence of HPV16 followed by Europe, North America and Asia,

whereas HPV 18 was also highest in South and Central America, followed by North America and Asia. There was virtually no HPV 18
detected in European patients (AdjPr = 0.82%, 95% CI = 0.73–0.92).
Clinical and demographic characteristics of HPV16/18-positive
lung cancer cases
The mean age of all lung cancer patients in the pooled dataset was
65.0 ± 10.1 (SD) years. The demographic and clinical characteristics
for all cases are presented in Table II; comparisons were made between
North American cases and the rest of the world. For the studies conducted in North America as well as the rest of the world, a higher
proportion of the patients were male (53 and 72%, respectively), ever
smokers (84 and 76%, respectively) and most of the lung cancers were
not SCC (64 and 62%, respectively). North American patients were
mostly White (89%) in contrast to the rest of the world where the
majority were non-White (57%). Early-stage lung cancers were more
represented in the North American studies (63%) in contrast to only
50% in studies from the rest of the world. For each geographic subgroup, there were no noted differences in the proportion of HPV16/18
patients according clinical and demographic characteristics with the
exception of race. The majority of patients in North America were
White and a higher proportion of HPV 16/18-positive lung cancers
were also noted among White patients (72%). However, for the rest of
the world, although a near equal proportion of White and non-White
patients were included, the majority of HPV 16/18-positive lung cancers were observed in non-White patients (88%).
No statistically significant associations were observed between
HPV16/18-positive lung tumors and gender, age, smoking history,
stage and histology (Table III). However, HPV 16/18-positive lung cancer cases were less likely to be observed among White patients compared with non-White patients (adjusted odds ratio [Adj OR] = 0.33,
95% CI = 0.12–0.90). For larger studies, (≥100 cases, 4 studies with
a minimum of 131 cases and a maximum of 399 cases), the association of HPV 16/18 with race persisted (White: Adj OR = 0.08, 96%
CI = 0.02–0.33). For smaller studies (<100 cases, 16 studies with a minimum of 22 cases and a maximum of 99 cases), the HPV 16/18-positive

Table II. Comparisons of demographic characteristics of patients according to HPV16/18 status (published datasets only)
Characteristic

Gender
Male
Female
Age (years)
≤66
>66
Race
White
Othersb
Smoking history
Never smoked
Ever smoked
Histology
SCC
Othersc
Stage
0/Id
II
III
IV

Asia, Europe and South/Central America
Total (N = 2500)

HPV16/18
positive
(N = 233,
9.3%)

HPV16/18
negative
(N = 2267,
90.7%)

1749 (71.92)
683 (28.08)

154 (66.96)
76 (33.04)

1595 (72.43)
607 (27.57)

1212 (51.33)
1149 (48.67)

92 (42.4)
125 (57.6)

1120 (52.24)
1024 (47.76)

1083 (43.32)
1417 (56.68)

27 (11.59)
206 (88.41)

1056 (46.58)
1211 (53.42)

602 (24.06)
1898 (75.94)

67 (28.93)
166 (71.07)

534 (23.56)
1733 (76.44)

953 (38.12)
1547 (61.88)

107 (45.92)
126 (54.08)

846 (37.32)
1421 (62.68)

1240 (49.60)
460 (18.41)
479 (19.14)
321 (12.84)

108 (46.52)
36 (15.41)
43 (18.37)
46 (19.70)

1132 (49.92)
424 (18.72)
436 (19.22)
275 (12.14)

North America
P valuea

Total (N = 663)

HPV16/18
positive
(N = 23,
3.5%)

HPV16/18
negative
(N = 640,
96.5%)

349 (52.64)
314 (47.36)

10 (43.48)
13 (56.52)

339 (52.97)
301 (47.03)

315 (47.51)
348 (52.49)

10 (43.48)
13 (56.52)

305 (47.66)
335 (52.34)

239 (88.52)
31 (11.48)

13 (72.22)
5 (27.78)

226 (89.68)
26 (10.32)

104 (15.69)
559 (84.31)

3 (13.04)
20 (86.96)

101 (15.78)
539 (84.22)

239 (36.43)
417 (63.57)

5 (22.73)
17 (77.27)

234 (36.91)
400 (63.09)

422 (63.63)
106 (16.01)
109 (16.43)
26 (3.93)

15 (65.65)
1 (5.59)
3 (13.91)
4 (16.52)

407 (63.59)
105 (16.39)
106 (16.53)
22 (3.48)

0.157

P valuea

0.632

0.529

0.557

0.059

0.102

0.762

0.256

0.536

0.345

0.614

0.099

Data are presented as number of patients (%).
a
P value was calculated by a logistic regression model with study as a random effect.
b
Others include Black, Hispanic, Asian and race not specified.
c
Others include adenocarcinoma and histology not specified.
d
Includes four cases with stage 0 (in situ).
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Table III. Association of demographic and clinical variables with HPV 16/18 (published datasets only in all regions)
Variable

HPV16/18 positive
Small studiesa (N = 918)

All studies (N = 3163)
ORc (95% CI)
Gender
Male
Female
Age (years)
≤66
>66
Race
Othersd
White
Smoking history
Never smoked
Ever smoked
Histology
Otherse
SCC
Tumor stage
I/II
III
IV

P value

ORc (95% CI)

0.141
1.0 (ref.)
1.27 (0.92, 1.75)

Large studiesb (N = 2245)
P value
0.049

1.0 (ref.)
1.61 (1.00, 2.59)
0.420

1.0 (ref.)
1.13 (0.84, 1.54)

0.708

0.930

0.859

0.812

0.974
1.0 (ref.)
1.01 (0.59, 1.74)

0.576
1.0 (ref.)
1.16 (0.69, 1.93)

0.561
1.0 (ref.)
0.87 (0.56, 1.37)
1.10 (0.66, 1.85)

< 0.001
1.0 (ref.)
0.08 (0.02, 0.33)

1.0 (ref.)
1.06 (0.58, 1.91)

1.0 (ref.)
1.05 (0.71, 1.54)

0.361
1.0 (ref.)
0.82 (0.54, 1.25)

1.0 (ref.)
0.80 (0.25, 2.59)

1.0 (ref.)
1.02 (0.66, 1.57)

0.824

0.029

0.029

0.827
1.0 (ref.)
0.94 (0.53, 1.66)

0.044
1.0 (ref.)
0.94 (0.53, 1.66)
2.55 (1.08, 6.04)

P value

1.0 (ref.)
1.05 (0.68, 1.62)

1.0 (ref.)
1.65 (1.05, 2.59)

1.0 (ref.)
0.33 (0.12, 0.90)

ORc (95% CI)

0.338
1.0 (ref.)
0.78 (0.36, 1.68)
0.68 (0.36, 1.27)

Ref.: reference level.
a
Small studies include studies with 22 ≤ number of cases ≤ 99.
b
Large studies include studies with 131 ≤ number of cases ≤ 399.
c
Study was included as a random effect.
d
Others include Asian, Black, Hispanic and race not specified.
e
Others include adenocarcinoma and histology not specified.

patients were more likely to be female (Adj OR = 1.61, 95% CI = 1.00–
2.59), older than 66 years (Adj OR = 1.65, 95% CI = 1.05–2.59) and
diagnosed with stage IV tumors than stage I/II (Adj OR = 2.55, 95%
CI = 1.08–6.04). There were no differences in the association of HPV
with stage IV tumors when we compared studies that reported verification of cancer diagnosis to those that did not report verification of
cancer diagnosis in their publication. Similarly, for studies that reported
efforts to avoid contamination, there was no difference in the association of HPV16/18 with stage IV tumors compared with those studies that did not include this information in their publication (data not
shown). When North American studies were evaluated separately, there
was no association of HPV 16/18 with gender, age, smoking history or
histology and a marginal association with race was observed, which
was significant for larger studies only (data not shown).
HPV prevalence in normal versus lung cancer tissues
There were 16 studies that evaluated HPV prevalence in lung cancer tissues (1208 cases) in addition to normal lung tissues (732 controls). Normal lung tissues were either from lung cancer patients (i.e.
adjacent normal or non-adjacent normal, n = 255) or from normal
lung tissues from non-cancer patients (n = 477). Lung cancer tissues
were almost four times more likely to be positive for any HPV DNA
compared with normal (OR = 3.86, 95% CI = 2.87–5.19; study was
included as a random effect).
Evidence of HPV16/18 DNA integration in lung cancer
Because integration of high-risk HPV DNA correlates with the overexpression of HPV oncogenes, we investigated the physical status
of HPV16 in a subset of cases. In our pooled international dataset,
physical status data were available for three studies conducted in
Asia, South/Central America and North America (32,48,49) (n = 28,
HPV16-positive patients). For the HPV16-positive lung tumors, 75%
(21/28) carried integrated HPV16 genomes, 3.6% (1/28) carried episomal HPV16 genomes and 21.4% (6/28) carried both integrated and
episomal forms of HPV16 DNA. There was no significant difference
in the distribution of HPV physical status according to each study
(P = 0.436).
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An equal number of male and female patients were HPV16 positive, but the majority of female patients, i.e. 92.9% (13/14), carried
integrated HPV 16 DNA compared with 57% (8/14) of male patients
(Table IV). None of the female patients had episomal HPV genomes
in their tumors and only 7.1% (1/14) had both integrated and episomal
forms. On the other hand, 7.1% (1/14) of male patients had episomal
HPV genomes, and 35.7% (5/14) had both integrated and episomal
HPV genomes in their tumors.
Survival analysis
A subset of patients had available follow-up data for four published
studies (11,31,55,56) (n = 451). For all patients combined, the 2 year
and 5 year overall survival rates for HPV16/18-negative patients were
60.9 and 38.5%, respectively, whereas the 2 year and 5 year overall
survival rates for HPV16/18-positive patients were 71.4 and 64.3%,
respectively. The Kaplan–Meier curves according to HPV16/18 status
(data not shown) were not statistically significantly different (log-rank
P value = 0.263).
Discussion
To date, >100 studies (including case reports) have analyzed HPV
DNA in lung cancers (7). Although the majority of these studies have
reported the prevalence of HPV16 and/or 18 DNA and a few publications have shown evidence of HPV oncogene (E6 and E7) expression (12,57), definite evidence of a causal relationship is still missing.
Previously published meta-analyses of HPV in lung cancer show that
HPV16 and HPV18 are the two most common genotypes detected in
lung tumors worldwide (5–7); however, the characteristics of patients
with these tumors were not determined. This study is the first international pooled analysis of individual data received from various
research groups and was focused to define the demographic, behavioral and clinical characteristics of lung cancer cases with HPV16 and/
or 18 DNA. We have also for the first time reported and compared
published data from five North American studies with other parts
of the world. Similar to previous reports, as expected, in our study
(5–7), HPV16 and/or 18 were the most prevalent high-risk genotypes

HPV and lung cancer

Table IV. HPV 16 physical status in primary lung carcinomas
Case

Age

Sex

Histology

Physical status

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
SiHa
Caski

69
84
67
74
62
58
66
75
70
72
80
72
55
79
59
74
71
70
74
69
78
68
59
63
69
39
66
62

Female
Male
Male
Male
Female
Male
Female
Male
Female
Female
Male
Female
Female
Male
Female
Female
Female
Male
Male
Male
Male
Male
Female
Male
Female
Female
Male
Female

Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
SCC
Adenocarcinoma
SCC
Adenocarcinoma
SCC
Adenocarcinoma
Adenocarcinoma
SCC
Adenocarcinoma
Adenocarcinoma
SCC
Adenocarcinoma
SCC
Adenocarcinoma
SCC
SCC
Adenocarcinoma
SCC
SCC
Adenocarcinoma
Adenocarcinoma
Adenocarcinoma
SCC
SCC
Adenocarcinoma

Mixed
Integrated
Integrated
Mixed
Integrated
Integrated
Integrated
Integrated
Integrated
Integrated
Mixed
Integrated
Integrated
Integrated
Integrated
Integrated
Integrated
Mixed
Integrated
Integrated
Mixed
Episomal
Integrated
Integrated
Integrated
Integrated
Mixed
Integrated
Integrated
Mixed

Mixed: integrated and episomal genomes.

detected in lung cancers, but still counting for a low fraction of lung
cancers and with heterogeneity among studies.
It is plausible that differences in the geographic location, study size,
demographic and clinical makeup of each study could contribute to
heterogeneity in HPV prevalence between studies. Furthermore, the
majority of studies included in this pooled analysis were small (<100
cases) and may be less representative samples, thus contributing to
heterogeneity in HPV prevalence. Therefore, for each geographic
region, the prevalence of HPV 16/18 was adjusted for each study
as well as potential confounders yet variations in HPV16/18 prevalence remained. The highest prevalence of HPV16/18-positive lung
cancers was observed in South and Central American, whereas North
American and Asian studies had similar prevalence and European
studies had significantly lower prevalence of HPV 16/18. Similar
observations were made for HPV 16 and HPV 18 independently.
However, within each geographic region, distinct differences in the
prevalence of HPV 16 and HPV18 genotypes were noted with the
exception of Asia and North America. In North America, although the
prevalence of each genotype was low, the prevalence of HPV 18 was
slightly higher than that of HPV 16. In contrast, for Asia, Europe and
South and Central America, if any HPV DNA detected in lung cancer,
HPV 16 appeared to be more prominent than HPV18. In Europe, the
prevalence of HPV18 was near zero. Factors that may be responsible
for variability in HPV prevalence could be sexual behaviors of participants, genetics and possible environmental contamination as argued
in the study by Koshiol et al. (54).
In addition to geographic location, the recent meta-analysis by
Syrjanen et al. (7) reported that the heterogeneity between studies
might be related to differences in histologic type. In this study, there
were no differences in the proportion of histologic types in North
America compared with the rest of the world and we observed no
association of HPV 16/18 status with histology. Although South and
Central American studies had the highest HPV prevalence, there were
only two studies from this region; therefore, this finding will need
to be confirmed by additional studies. Second to South and Central
America, we observed that Asia had the highest prevalence of HPV

16 and 18. A significant association of HPV 16/18 DNA was also
observed with race, where non-White lung cancer patients were more
likely to have HPV-positive tumors compared with White lung cancer
patients. There may be a number of reasons for this observed difference in HPV prevalence some of which might include differences in
sexual practices or differences in susceptibility. Further investigation
of the potential reasons for the racial difference in the association of
HPV16/18 is needed.
Park et al. (65) evaluated HPV status in 112 non-small-cell lung
cancer patients from Korea and reported that HPV16 was more common in younger lung cancer patients and HPV18 was more common
in patients diagnosed with advanced stage. Although we categorized
HPV16 and HPV18-positive tumors into a single group, we found no
associations with age or stage, neither for gender, smoking history
or histology. However, for small studies only, HPV16/18 was associated with old age (>66 years), female gender and advanced stage. It is
possible that patients with metastatic disease (by definition, stage IV)
could include metastases from other or mixed tumors, such as head
and neck or cervical cancers (59), and the resulting misclassification
could account for some of these findings. Therefore, the association
with older females with stage IV tumors warrants further investigation
in a single, larger and more representative study.
Although HPV-positive oropharyngeal cancers have been found
to be associated with non-smokers, these tumors are also associated with patients having lower number of pack-years of cigarettes
compared with heavy smokers (66). In vitro studies also show that
tobacco smoke carcinogens have been shown to increase HPV16 and
18 viral synthesis as well as interact with HPV16 E6/E7 oncoproteins
to increase lung cell proliferation (67). Furthermore, smoking suppresses the host innate immunity including functional and structural
changes in the respiratory ciliary epithelium, lung surfactant protein
and immune cells in the lung (68), thus may facilitate HPV infection
and persistence in the lung in a subset of tumors. Mechanistically, it is
not yet clear how HPV might promote lung carcinogenesis; however,
the cooperation between HPV and tobacco smoke carcinogens for
lung carcinogenesis is plausible. In this study, the association of HPV
with smoking status was not conclusive. Therefore, further studies are
needed to investigate the relationship between HPV and smoking status among patients with HPV-positive lung tumors.
Although our study cannot conclusively confirm the carcinogenetic role of HPV in lung cancer, we have shown that lung cancer
tissues were almost 4-fold more likely to be HPV-positive compared
with normal lung tissues. Secondly, our preliminary investigation of
HPV16/18 physical status among a subset of tumors shows that the
majority of the female tumors carried integrated HPV DNA while the
physical status of HPV16/18 in male tumors was inconsistent. Given
the predominance of integrated HPV genomes in female lung cancer patients, it is possible that HPV may play a role in lung cancer
development but is unlikely to contribute to a large proportion of lung
cancer cases. Although the presence of integrated DNA would suggest that the DNA detected was not simply due to contamination, it is
important to note that there are no published studies comparing E2/
E6-based integration with direct integration detection methods, which
are more reliable. Thus, the results must be interpreted with caution.
Our findings suggest an association of HPV DNA with a small fraction of lung tumors, with large geographic variations, but further
comprehensive analysis is needed to assess whether this association
reflects a causal relationship. Such detailed analysis should include
not only HPV DNA testing but evaluation of all criteria that were
postulated to prove a causal involvement of HPV in carcinogenesis,
such as p16 expression and HPV E6/E7 oncogene expression (2,69),
and measures to exclude pulmonary metastases (59).
The survival data in this pooled analysis only included 14
HPV16/18-positive cases and 5 events, and there were no significant differences between the Kaplan–Meier curves. However, based
on the 2 and 5 year survival rates between HPV16/18-positive
and HPV16/18-negative patients, there was some suggestion that
HPV16/18-positive lung cancer patients had improved survival.
This trend toward improved survival is consistent with HPV-related
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carcinogenesis in non-cervical sites, such as the head and neck and
penile cancer, where HPV-positive cancer patients have an improved
overall and disease-free survival compared with HPV-negative
patients (70–72). This observation needs to be verified in a much
larger number of cases/events and adjustment for known prognostic
factors including a history of HPV-related disease as well as treatment
for previous HPV-related disease.
The availability of individual data from each study included in the
analysis reduces the potential errors associated with aggregate data.
However, a number of limitations are inherent in this study design as
well. One of these limitations is the lack of a uniform gold standard
in the HPV DNA detection methods leading to variability in HPV
prevalence. Only 27 of the 81 eligible studies participate in this analysis. We have compared the characteristics of the cases in the pooled
dataset and with that of the non-included studies and remain confident
that both subsets are similar in characteristics. Nevertheless, possible
selection bias cannot completely be ruled out. Although the overall
sample size was large, some of the subgroup analyses included small
numbers. Although this study has good representation of populations from the Americas, Europe as well as Asia, China, Korea and
Taiwan were not as well represented. In addition, the North American
dataset was limited, in that, the majority of cases were of European
descent; a larger US study with broad ethnic diversity is needed to
allow for further investigation related to HPV and race. Although the
present analysis provides evidence in favor of an association of HPV
DNA with a small subset of lung cancer, these findings need to be
validated and further comprehensive analysis is needed to examine a
potential causal relationship. A detailed analysis of a larger and more
representative case series, including the testing of all criteria that were
postulated to prove a causal involvement of HPV in carcinogenesis
and excluding pulmonary metastases, needs to be performed. Most
importantly, the preliminary evidence on the potential prognostic role
of HPV in lung cancer needs confirmation because of its potential
clinical implications, e.g. in therapy of lung cancer.
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